Author

Sean Lilienfeld

Observed names: S. LILIENFELD, S. Lilienfeld

Observed institutions: Brigham and Women's Hospital, Southwestern Vermont Health Care, Beth Israel Deaconess Medical Center, Cleveland Clinic, Janssen (Belgium), Inserm, Washington University in St. Louis, University of Rochester Medicine, Boston Scientific (United States), Institut de Psychiatrie et Neurosciences de Paris, Janssen (United States), The Memory Clinic, Université Paris Descartes, Codman & Shurtleff, Inc. (United States), The University of Texas Health Science Center at Houston

OpenAlex ID: A5023626549

A 5-month, randomized, placebo-controlled trial of galantamine in AD

2000 · P.N. Tariot, P.R. Solomon, et al. · Neurology · 915

Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial

2002 · Timo Erkinjuntti, Alexander Kurz, et al. · The Lancet · 750

Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial

2000 · G. K Wilcock, S. Lilienfeld, et al. · BMJ · 623

PDF

Galantamine — a Novel Cholinergic Drug with a Unique Dual Mode of Action for the Treatment of Patients with Alzheimer's Disease

2002 · Sean Lilienfeld · CNS Drug Reviews · 310

A Long-Term Comparison of Galantamine and Donepezil in the Treatment of Alzheimer???s Disease

2003 · Gordon Wilcock, Ian Howe, et al. · Drugs & Aging · 210

Stroke Treatment Academic Industry Roundtable X

2019 · Sean I. Savitz, Jean-Claude Baron, et al. · Stroke · 201

APOE Genotype: No Influence on Galantamine Treatment Efficacy Nor on Rate of Decline in Alzheimer’s Disease

2001 · Jeroen Aerssens, Peter Raeymaekers, et al. · Dementia and Geriatric Cognitive Disorders · 91

An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia

2003 · Timo Erkinjuntti, Alexander Kurz, et al. · Clinical Therapeutics · 79

Cerebrospinal shunt infection in patients receiving antibiotic-impregnated versus standard shunts

2011 · Scott L. Parker, William N. Anderson, et al. · Journal of Neurosurgery Pediatrics · 64

Long‐term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer's disease with cerebrovascular disease

2003 · A. F. Kurz, T. Erkinjuntti, et al. · European Journal of Neurology · 53

Management of Patients with Alzheimer’s Disease plus Cerebrovascular Disease: 12-Month Treatment with Galantamine

2003 · Roger Bullock, Timo Erkinjuntti, et al. · Dementia and Geriatric Cognitive Disorders · 49

2003 · Jeffrey S. Markowitz, Elane M. Gutterman, et al. · SLEEP · 42

Galantamine: Additional Benefits to Patients with Alzheimer’s Disease

2000 · Sean Lilienfeld, Wim Parys · Dementia and Geriatric Cognitive Disorders · 39

Galantamine in the Treatment of Cognitive Decline in Patients with Vascular Dementia or Alzheimer???s Disease with Cerebrovascular Disease

2003 · Gary Small, Timo Erkinjuntti, et al. · CNS Drugs · 37

The Use of Implanted Programmable Infusion Pumps in the Management of Nonmalignant, Chronic Low-Back Pain

2007 · Peter Staats, Michael Whitworth, et al. · Neuromodulation Technology at the Neural Interface · 19

Galantamine alleviates caregiver burden in Alzheimer's disease: A 6-month placebo-controlled study

2000 · Gordon K. Wilcock, Sean Lilienfeld · Neurobiology of Aging · 14

A novel metric for treatment durability in clinical trials of minimally invasive treatments for benign prostatic hyperplasia

2020 · Larry E. Miller, Alexis E. Te, et al. · Expert Review of Medical Devices · 10

Relevant clinical outcomes in probable vascular dementia and Alzheimer's disease with cerebrovascular disease

2002 · John O'Brien, Sean Lilienfeld · Journal of the Neurological Sciences · 10

Cholinesterase Inhibitors for Alzheimer Disease

2003 · S. Lilienfeld · JAMA · 7

ApoE genotype: No influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease

2000 · Jeroen Aerssens, Sean Lilienfeld, et al. · Neurobiology of Aging · 7

Broad Therapeutic Benefits in Patients with Probable Vascular Dementia or Alzheimer's Disease with Cerebrovascular Disease Treated with Galantamine

2002 · S. LILIENFELD, A. KURZ · Annals of the New York Academy of Sciences · 4

Comparative Effectiveness Research in the Regulatory Setting

2012 · Jay P. Siegel, Norman Rosenthal, et al. · Pharmaceutical Medicine · 3

Long-term safety, tolerability, and efficacy of galantamine in the treatment of probable vascular dementia or Alzheimer's disease with cerebrovascular disease: An interim analysis

2003 · Alexander Kurz, Timo Erkinjuntti, et al. · mediaTUM (Technical University of Munich) · 3

Medical Affairs in MedTech

2023 · William Sigmund, John Pracyk, et al. · Medical Affairs · 1

A Nonradiographic System for Assessing Pressure for the Codman-Hakim Programmable Valve

2010 · Nancy Olsen Bailey, Mark Luciano, et al. · Operative Neurosurgery · 1

Works count: 34

Citation count: 3,543

H-index: 15

I10-index: 18